Hemoglobin subunit gamma 1 (HBG1) regulatory DNA (HBG1 regulatory DNA)

Hemoglobin subunit gamma 1 (HBG1) regulatory DNA refers to the specific genomic sequences, including the promoter and distal regulatory elements, that control the expression of the gamma-globin gene. In healthy adults, these DNA regions are typically silenced by the binding of repressor proteins such as BCL11A and ZBTB7A, facilitating the developmental switch from fetal hemoglobin (HbF) to adult hemoglobin (HbA) (Martyn et al., 2018, Nature Genetics; PMID: 29632378). This regulatory region is a primary therapeutic target for treating beta-hemoglobinopathies, such as Sickle Cell Disease and Beta-Thalassemia, where adult hemoglobin is either defective or absent. Therapeutic strategies targeting HBG1 regulatory DNA utilize gene editing technologies, such as CRISPR/Cas9, Cas12a, or base editors, to disrupt repressor binding sites or introduce mutations that mimic Hereditary Persistence of Fetal Hemoglobin (HPFH) (Traxler et al., 2016, Nature Medicine; PMID: 27348501). By preventing the binding of repressors or enhancing the recruitment of activators, these interventions reactivate the production of HbF in erythroid cells. The induction of HbF serves to dilute sickle hemoglobin (HbS) and provide functional oxygen-carrying capacity, thereby reducing vaso-occlusive crises and anemia in patients (Editas Medicine, 2023; Beam Therapeutics, 2023).

Other names

HBG1 promoterGamma-globin regulatory elementHBG1/HBG2 promoter regionFetal hemoglobin regulatory DNADistal CCAAT box of HBG1

Disruption of transcriptional repressor binding sites or introduction of HPFH-like mutations via gene editing to induce fetal hemoglobin (HbF) expression.